Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

View Full Paper
Ask AI
Bookmark
Share

Authors

EJEllie JohnVOVictoria Otero

Discussion

Loading...

Member takes

Overview

Updated analysis demonstrates improved progression-free survival in mantle cell lymphoma with ABR, suggesting better treatment outcomes.

Key Points

  • Median time to third-line therapy is significantly longer with bendamustine-rituximab plus acalabrutinib treatment.
  • Improved median progression-free survival was seen compared to placebo plus bendamustine-rituximab.
  • Randomized phase 3 trial data showed that ABR reduced the risk of subsequent therapy initiation in patients.
  • No long-term safety concerns were observed with prolonged acalabrutinib exposure in patients receiving treatment.

Cite This Study

John et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d96ahttps://doi.org/10.1182/blood-2025-885
View Full Paper
Ask AI
Bookmark
Share